National Institute on Alcohol Abuse and Alcoholism (NIAAA)

The Laboratory of Cardiovascular Physiology and Tissue Injury (LCPTI) seeks to understand the cellular and molecular mechanisms of the complex interplay of oxidative/nitrative stress, inflammation, lipid signaling (for example endocannabinoid signaling) and cell death pathways (e.g. poly(ADP)-ribose polymerase) in tissue injury, and to identify new therapeutic targets using clinically relevant animal models of disease (e.g., ischemia reperfusion injury, cardiomyopathies/heart failure...

2024 May 7, 2024 [PDF – 664 KB] February 8, 2024 [PDF – 664 KB] 2023 September 7, 2023 [PDF – 888 KB] May 9, 2023 [PDF – 694 KB] February 9, 2023 [PDF – 550 KB] 2022 September 8, 2022 [PDF – 438 KB] May 10, 2022 [PDF – 625 KB] February 10, 2022 [PDF – 671 KB]

Click to view full text description . Click the link below to download a pdf version with alternative text included.

As a federal agency, NIAAA works continually to uphold the values of responsible stewardship, research integrity, and public trust. These values are reinforced by NIAAA’s commitment to optimal management and accountability, strategic collaboration, and communication of research results. Objective 1: Ensuring Optimal Management and Accountability NIAAA strives to continually optimize operations across its administrative and scientific functions through sound, data-driven...

Structure of the Strategic Plan The National Institute on Alcohol Abuse and Alcoholism (NIAAA) Strategic Plan: Fiscal Years 2024–2028 describes research goals, themes, and programs that support the NIAAA mission. These goals also support the NIH-Wide Strategic Plan for Diversity, Equity, Inclusion, and Accessibility: Fiscal Years 2023–2027 , as well as complement other National Institutes of Health (NIH) strategic plans...

NIAAA’s ability to pursue its research priorities is supported by the commitment to building and sustaining a robust research capacity. At the core of NIAAA’s efforts to build research capacity are cultivating a talented and diverse scientific and administrative workforce to advance research to the next frontier and maximizing NIAAA research resources and infrastructure to promote discovery. Objective 1: Enhancing...

Data Access Policy, Application and Agreement Description The National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III) was sponsored, designed and directed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Study Details Sponsor: The National Institute on Alcohol Abuse and Alcoholism NCT #: 01273220 Study Type: Observational Number of Participants: 36,309 Population: A cross-sectional, nationally representative sample of...

Data Access Policy, Application and Agreement NIAAA Protocol NCIG 001: A Multisite Double-Blind, Placebo-Controlled Trial of Quetiapine Fumarate XR in Very Heavy-Drinking Alcohol-Dependent Patients Description  This double-blind, randomized placebo-controlled trial evaluated the efficacy and safety of quetiapine, for the treatment of alcohol use disorder (AUD).   Study Details  Sponsor: The National Institute on Alcohol Abuse and Alcoholism’s Clinical Investigations Group (NCIG) ...

Description The COMBINE Study is the largest pharmacotherapy trial conducted for Alcohol Use Disorder in the United States. This clinical trial evaluated the efficacy of naltrexone and acamprosate, both alone and in combination, in the context of medical management with and without Combined Behavioral Intervention (CBI). Study Details Sponsor: The National Institute on Alcohol Abuse and Alcoholism NCT #: 00006206...

Access to the NIAAA NESARC-III data set will only be provided to qualified research investigators who, along with their institutions, have certified their agreement with the terms of access detailed in the NIAAA NESARC-III Data Access Application and the NIAAA Data Use Agreement. Please note that review and signature from your institutional authorized signatory is required. This is ordinarily someone...

Prevalence of Underage Alcohol Use, People Ages 12 to 20 Prevalence of Lifetime Drinking According to the 2022 National Survey on Drug Use and Health (NSDUH), 13.2 million people ages 12 to 20 (34.2% in this age group) reported that they have had at least one drink in their lives. 1,2 This includes: 6.5 million males ages 12 to 20...

Scientists have identified an area within the brain’s frontal cortex that may coordinate an animal’s response to potentially traumatic situations. Understanding where and how neural circuits involving the frontal cortex regulate such functions, and how such circuits could malfunction, may provide insight about their role in trauma-related and stress-related psychiatric disorders in people. The study, led by scientists at the...

The rate of all alcohol-related emergency department visits increased 47.0% between 2006 and 2014, which translates to an average annual increase of 210,000 alcohol-related emergency department visits. 1 Estimates suggest that alcohol played a role in at least 7.1% of emergency department visits and 17.4% of deaths due to opioid overdoses in 2020. 2,3 The Alcohol-Related Disease Impact application estimates...

Description This large, multisite clinical trial evaluated the efficacy and safety of gabapentin enacarbil extended-release (GE-XR) (HORIZANT®), a gabapentin prodrug formulation for the treatment of alcohol use disorder (AUD). Study Details Sponsor: The National Institute on Alcohol Abuse and Alcoholism’s Clinical Investigations Group (NCIG) NCT #: 02252536 Phase: Phase 2 Treatment Arms: Horizant® (gabapentin enacarbil) 600mg twice a day and...

Data Access Policy, Application and Agreement NIAAA Protocol NCIG 002: A Multisite Double-Blind, Placebo-Controlled Trial of Levetiracetam Extended-Release in Very Heavy-Drinking Alcohol-Dependent Patients Description This multisite clinical trial evaluated the efficacy and safety of levetiracetam XR, for the treatment of alcohol use disorder (AUD). Study Details Sponsor: The National Institute on Alcohol Abuse and Alcoholism’s Clinical Investigations Group (NCIG) NCT #...

Data Access Policy, Application and Agreement NIAAA Protocol NCIG 003: A Phase 2, Double-Blind, Placebo Controlled Trial to Assess the Efficacy of Varenicline Tartrate for Alcohol Dependence Description This double-blind, randomized placebo-controlled trial evaluated the efficacy and safety of varenicline tartrate for the treatment of alcohol use disorder (AUD). Study Details Sponsor: The National Institute on Alcohol Abuse and Alcoholism’s...